By ANDREW POLLACK
The vote on flibanserin by an advisory panel to the Food and Drug Administration follows two rejections and a campaign for the drug’s approval.
Published: June 5, 2015 at 12:00AM
from NYT Business Day http://ift.tt/1MqOyo1
from WordPress http://ift.tt/1cApq1k
via Hadi Aboukhater
No comments:
Post a Comment